China Healthcare Weekly (May.5)- 2nd Wave of COVID, Valuation Logic of China's Core Assets, Lifetech
It's time to talk about the 2nd wave of COVID in China.Investors need to understand deep meaning/valuation logic of China's core assets so as not...
272 Views
Zhejiang Supcon Technology GDR Listing - Momentum Has Been Strong and Not a Large Deal to Process
Zhejiang Supcon Technology (688777 CH) is looking to raise around US$347m in its Swiss GDR listing. Huatai and CLSA are bookrunners on the deal.
360 Views
China Healthcare Weekly (Apr.7)- Pacemaker VBP, FDA Changes Game Rule, Industry Beta Vs Fundamentals
China starts pacemaker VBP, which worth investors' vigilance. FDA changes game rules on accelerated approval standards. Beta disappears without...
376 Views
Fangda Carbon New Material GDR Listing - Share Price Has Outperformed Index over the past 3 Months
Fangda Carbon New Material Co, Ltd. (600516 CH) is looking to raise around US$124m in its Swiss GDR listing. Huatai is the sole bookrunner in the...
443 Views
Shandong Weigao Group Medical Polymer (1066.HK) - As a Holding Platform, Investment Value Is Limited
Weigao is lack of core competitiveness due to weak R&D. Its performance could improve after China reopens, but Weigao could still underperform its...
341 Views